French life science park celebrates record investment haul
Biocitech, a life science technology park in Paris, France, is celebrating after having raised around EUR 90 million in 12 months. Achievements to date include 20 patents, more than 25 partnerships between resident companies, two clinical trials, nine 'major scientific advances' and 25 publications in peer-review journals. The companies hosted at Biocitech raised €89.8 million in the 12 months leading up to September, which is more than that raised by any other single French site for the same period. This has marked out Biocitech as 'one of the leading technology parks in Europe', according to the park's owners. Much of the park's success has been attributed to collaboration between resident companies. Some 25 new agreements were signed between these companies over the last year, while an additional 30 were sealed with external institutions or companies. 'The impressive number of partnerships between our residents provides backing for our policy of encouraging them to use the synergies that exist between them and to increase the 'campus-effect' we have here,' said Biocitech director Jacques Lhomel. Along with other organisations in the Ile-de-France region, Biocitech is involved in the Medicen Paris Region network, a healthcare and new therapy cluster that the French Government believes is internationally competitive. Members of the network qualify for financial support from the Government.
Countries
France